THE USE OF SINGLE SAMPLE CLEARANCE ESTIMATES TO PROBE HEPATIC DRUG-METABOLISM - HANDPRINTING THE INFLUENCE OF CIGARETTE-SMOKING ON HUMAN HEPATIC DRUG-METABOLISM

被引:10
作者
BACHMANN, KA
NUNLEE, M
MARTIN, M
SCHWARTZ, J
JAUREGUI, L
FORNEY, RB
机构
[1] MED COLL OHIO,DEPT PATHOL,TOLEDO,OH 43606
[2] ST VINCENTS MED CTR,TOLEDO,OH 43606
关键词
D O I
10.3109/00498259009046868
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Conditions were examined under which estimates of drug clearance made from a single measurement of plasma concentration effectively represented multiple-sample estimates of clearance for quinidine, valproic acid, unbound valproic acid, and lorazepam. When plasma concentrations were measured at various post-dose times, both individual and mean values of single-sample clearance estimates, CL, corresponded closely to multiple-sample clearance estimates. Best post-dose sampling times were: quinidine, 8 h; valproic acid, 24 h; and lorazepam, 24 h. 2. Single-sample clearance estimates, CL, were calculated for seven drugs employed as probes of human hepatic drug-metabolizing enzymes. Valproic acid was used to probe microsomal and peroxisomal oxidase activity; antipyrine, phenytoin, quinidine, carbamazepine, and theophylline were used as probes of hepatic mixed-function oxidases (MFO), and lorazepam as a probe for UDP-glucuronosyltransferase activity. 3. A clearance index (CI, namely probe CL for smokers divided by probe CL for non-smokers) was calculated for each probe. The effect of cigarette smoking (and presumably polycyclic aromatic hydrocarbon exposure) on all probe CL values was consolidated and plotted as the logarithm of the CI to produce a handprint of drug metabolizing enzyme activity for cigarette smokers. 4. Only theophylline CL was significantly faster among smokers than non-smokers (P<0.01). 5. We conclude that the use of multiple probes of MFO activity when given in a single-dose, single-sample protocol for structuring handprints represents a minimally invasive and useful approach to characterize xenobiotic-mediated effects on hepatic MFO. © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码:537 / 547
页数:11
相关论文
共 34 条
[1]   SELECTIVITY OF CHOLESTYRAMINE TREATMENT ON HEPATIC MIXED-FUNCTION OXIDASE ACTIVITY [J].
BACHMANN, K ;
SCHWARTZ, J ;
FORNEY, R ;
SHERMAN, G ;
JAUREGUI, L .
PHARMACOLOGY, 1984, 29 (03) :128-141
[2]   PHENYTOIN AS A PROBE OF DRUG-METABOLISM - PREDICTING CLEARANCE WITH A SALIVARY SAMPLE [J].
BACHMANN, K ;
SCHWARTZ, J ;
FORNEY, R ;
JAUREGUI, L .
PHARMACOLOGY, 1985, 30 (03) :145-152
[3]  
BACHMANN K, 1986, INT J CLIN PHARM TH, V24, P546
[4]  
BACHMANN K, 1979, CLIN PHARMACOL THER, V25, P309
[5]   THEOPHYLLINE KINETICS - DOSE DEPENDENCY AND SINGLE SAMPLE PREDICTION OF CLEARANCE [J].
BACHMANN, K ;
SCHWARTZ, J ;
FORNEY, R ;
JAUREGUI, L .
PHARMACOLOGY, 1985, 30 (03) :136-144
[6]   THE SUITABILITY OF CARBAMAZEPINE AS A SINGLE-SAMPLE PROBE OF HUMAN MIXED-FUNCTION OXIDASE ACTIVITY [J].
BACHMANN, KA ;
SCHWARTZ, JI ;
JAUREGUI, L .
XENOBIOTICA, 1989, 19 (07) :711-719
[8]  
BAILLE T, 1990, ANTIEPILEPTIC DRUGS
[9]   ABSENCE OF EFFECT OF CIGARETTE-SMOKING ON SERUM CONCENTRATIONS OF SOME ANTICONVULSANTS IN EPILEPTIC PATIENTS [J].
BENETELLO, P ;
FURLANUT, M ;
PASQUI, L ;
CARMILLO, L ;
PERLOTTO, N ;
TESTA, G .
CLINICAL PHARMACOKINETICS, 1987, 12 (04) :302-304
[10]  
BURKE MD, 1987, DRUG METABOLISM MOL, P219